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www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMsigniﬁcant differences in the 77 matched pairs. Stent proﬁles were also similar in both
groups. Kaplan–Meier analysis (Figure) demonstrated no signiﬁcant differences in 1-
year (5% vs. 2.5%, p ¼ 0.59) or 2-year (20.7% vs. 11.5%, p ¼ 0.25) TLR between the
two groups.Conclusions: In our study, no additional beneﬁt of DCB plus DES combination was
found when compared to conventional DES implantation. However, a large ran-
domized study is essential to evaluate the efﬁcacy of DCB plus DES combination.
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Background: Recently, paclitaxel-coated balloon (PCB) has emerged as a potential
alternative to the current treatment of in-stent restenosis. However, the recurrent
restenosis still occurs in some cases. The predictors of recurrent restenosis are
incompletely understood. The aim of this study was to evaluate the predictors of
recurrent restenosis in patients treated with PCB for in-stent restenosis.
Methods: Data of the patients treated with PCB (SeQuent please) for in-stent reste-
nosis between 2008 and 2012 were collected. A total of 453 patients with 539 lesions
[(bare-metal stent restenosis (BMS-ISR); 113 lesions, drug-eluting stent restenosis
(DES-ISR); 426 lesions)] were analyzed in this study. Follow-up angiogram was
obtained in 476 lesions 6 months after procedure (follow-up rate: 88.3%). We eval-
uated the predictors of recurrent restenosis in patients treated with PCB for in-stent
restenosis.
Results: Recurrent restenosis occurred in 13 lesions (13.3%) of BMS-ISR and 79
lesions (20.9%) of DES-ISR. Target lesion revascularization was performed to 7 le-
sions (7.1%) of BMS-ISR and 54 lesions (14.3%) of DES-ISR. Late lumen loss was
lower in BMS-ISR than in DES-ISR (0.17 +/- 0.50 mm vs. 0.29 +/- 0.57 mm,
p¼0.04). Previous stent size  2.5mm (odds ratio [OR]: 1.84, 95% conﬁdence interval
[CI]: 1.13 to 3.02, p¼0.01), total occlusion lesions (OR: 2.74, CI: 1.15 to 6.36,
p¼0.02), and percentage diameter stenosis after procedure > 35% (OR: 1.72, CI: 1.03
to 2.85, p¼0.04) were independent predictors of recurrent restenosis.
Conclusions: Small vessels, total occlusion lesions, and residual stenosis >35% were
the predictors of recurrent restenosis in patients treated with PCB for in-stent
restenosis.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/DrTCT-279
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Background: In randomized clinical trials, efﬁcacy and safety of paclitaxel-coated
balloon (PCB) angioplasty for the treatment of bare-metal stent (BMS) and drug-
eluting stent (DES) restenosis was demonstrated. However there is few data if
different PCBs perform equally. This study aims to evaluate the long-term efﬁcacy of
two second-generation PCBs in treating coronary in-stent restenosis (ISR).
Methods: Between October 2010 and February 2012, all consecutive patients with ISR
lesions treated with the SeQuent Please PCB (B. Braun,Melsungen, Germany) or with
theDIORPCB (Eurocor GmbH,Bonn,Germany) at our institutionwere prospectively
included. Patients were followed up for 24 months by clinical observation. The primary
endpoint was the clinically driven target lesion revascularization (TLR) rate at 24
months. The secondary endpoint was the rate of major adverse cardiac events (MACEs),
deﬁned as a composite of cardiac death, myocardial infarction, and TLR at 24 months.
Results: 65 patients with 74 ISR lesions were included. 43 ISR lesions (21 BMS, 22
DES) were treated with the SeQuent Please PCB and 31 (11 BMS, 20 DES) with the
DIOR PCB. Baseline clinical, lesion characteristics and procedural data did not
signiﬁcantly differ between two groups. The TLR rate was signiﬁcantly lower in patients
with the SeQuent Please PCB compared with the DIOR PCB (4.7% vs. 22. 6%, p¼
0.03) at 24 months. The number of patients who suffered a MACE was not statistically
different across study groups, but a strong trend towards better clinical outcome was
discovered in the SeQuent Please PCB group (9.3 % vs. 25.8%, p¼0.058).
Conclusions: This real-world practice registry suggests that there are signiﬁcant differ-
ences in terms of TLR between two clinically available PCBs. The SeQuent Please PCB
demonstrated lower TLR rate compared to the DIOR PCB at 24 months follow-up.
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Background: The treatment of coronary in–stent restenosis (ISR) is challenging.
Drug–eluting stent (DES) implantation for ISR has not showed satisfactory results.
Drug–coated balloon (DCB) has been recently compared with DES for ISR treatment
with controversial results.
Methods: A systematic literature review in Pubmed/MEDLINE, Embase, Scopus, ISI
Web of Science, ScienceDirect electronic databases was performed to identify ran-
domized controlled trials (RCTs) comparing DCB with DES in ISR. No ﬁlters or
language restrictions were imposed. The keywords used were the following: “drug
coated balloon”, “drug eluting balloon”, and “paclitaxel eluting balloon”. The endpoint
was a composite of major adverse cardiovascular events (MACE) at 12 months, re-
ported as pooled risk ratio (RR) with 95% conﬁdence interval (CI). A DerSimonian-
Laird random-effects model was used. Heterogeneity was graded with I2 statistic.
Results: A total of 4 randomized controlled trials comparingDCB andDESwere identiﬁed.
Thepooled analysis showed a similar risk ofMACEat 12months between the two treatments
(RR 1.04, 95%CI 0.73–1.47, p¼0.83). The heterogeneity degreewas low (8.7%). However,
differently from the others, PEPCAD II trial exhibited a clear risk reduction with DCB (RR
0.45). To exclude a signiﬁcant impact of this trial on pooled RR, a sequential one study
removal was performed. Excluding PEPCAD II the pooled RR tended toward a modest RR
reduction associated with DES (RR 1.17, 95% CI 0.82–1.67, p¼0.38).Conclusions: DES implantation for ISR compared with DCB might lead to a modest
reduction in the risk of MACE at 12 months.ug-Eluting Balloons and Local Drug Delivery B81
